Clinical Trial Update: A Study of Patients With HER2 Gene Amplified Metastatic Breast Cancer Treated With First Line Herceptin and a Taxane

View source ↗

Summary

Clinical study of HER2-positive metastatic breast cancer patients treated with first-line trastuzumab (Herceptin) and a taxane; the trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)
• Taxane (paclitaxel or docetaxel)

Snippet

Sponsor: Genentech, Inc. | Conditions: Breast Cancer, Metastases | Status: COMPLETED